NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
Loading market information…
NSE · DRREDDY.NS · INR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dr. Reddy's Laboratories Limited’s forward annual dividend is ₹8.00 per share, paid annual. The forward yield is 0.59% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Dr. Reddy's Laboratories Limited’s next earnings report is currently expected on Jan 22, 2027, with estimated earnings per share of ₹12.24. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dr. Reddy's Laboratories Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Jul 23, 2025 | ₹17.04-7.29% vs estimate | ₹86.15B-0.99% vs estimate |
|---|
| Q4 2025 | May 9, 2025 | ₹19.09+5.12% vs estimate | ₹84.96B+1.3% vs estimate |
|---|
| Q3 2025 | Jan 23, 2025 | ₹16.94-5.42% vs estimate | ₹83.59B+2.24% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
₹4,580.00+₹23.00 (+0.5%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.76% below the high.
₹1,184.40+₹8.90 (+0.76%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 3.87% below the high.
₹1,358.00-₹7.60 (-0.56%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 14.77% below the high.
₹2,469.30-₹20.70 (-0.83%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.54% below the high.
₹1,659.90+₹15.10 (+0.92%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 4.6% below the high.
₹1,989.90+₹17.20 (+0.87%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 21.33% below the high.
₹3,074.50+₹25.50 (+0.84%)
Gland Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.04% below the high.
